In the year after an expert panel’s recommendation that women delay regular breast cancer screenings until age 50, the number of women in their 40s undergoing mammograms slightly declined, a new study shows.The study, carried out by the Mayo Clinic, found a drop of roughly 6 percent in the number of

In the year after an expert panel’s recommendation that women delay regular breast cancer screenings until age 50, the number of women in their 40s undergoing mammograms slightly declined, a new study shows.The study, carried out by the Mayo Clinic, found a drop of roughly 6 percent in the number of

The warning, stemming from an April inspection by U.S. regulators, does not restrict production or product shipments from the plant in La Aurora de Heredia, Costa Rica, Hospira said on Tuesday in a regulatory filing with the U.S. Securities and Exchange Commission.Among the issues cited by the FDA w

The Food and Drug Administration has agreed to give priority status to its review of three new uses for the anticlotting drug Xarelto, Johnson & Johnson announced Monday.The company is asking the agency to approve the drug to treat deep vein thrombosis and pulmonary embolism, and to prevent recu

New drugs for breast cancer and multiple myeloma won approval from the Food and Drug Administration on Friday, expanding options for patients in advanced stages of those diseases.The breast cancer drug, Afinitor from Novartis, seems to expand the time that endocrine therapy can keep the disease in c

Evidence-Based Decision-Making in Asia-Pacific with Rapidly Changing Health-Care Systems: Thailand, South Korea, and Taiwan. Thidaporn Jirawattanapisal1 Pritaporn Kingkaew2 Tae-Jin Lee3 Ming-Chin Yang4 1International Health Policy Program, Ministry of Public Health, Muang Nonthaburi,Thailand; 2

Evidence to Inform Decision Makers in Thailand: A Cost-Effectiveness Analysis of Screening and Treatment Strategies for Postmenopausal Osteoporosis. Pritaporn Kingkaew, BPharm, MSccorrespondenceemail, Usawadee Maleewong, BPharm, PhD, Chardpraorn Ngarmukos, MD, Yot Teerawattananon, MD, PhD Abst

(Reuters) – Europe’s medicines regulator, criticised in the past for excessive secrecy, is opening its data vaults to systematic scrutiny in a move that will let independent researchers trawl through millions of pages of clinical trial information.The change is a landmark in transparency that puts E

Abstract BACKGROUND: Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Essential Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand. This reimbursement policy has not covered for other genotypes of hepatitis

Abstract BACKGROUND: Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Essential Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand. This reimbursement policy has not covered for other genotypes of hepatitis C v